Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements
Written by Emily J. Thompson, Senior Investment Analyst
0mins
Should l Buy ?
Source: Newsfilter
Company Compliance Announcement: Portage Biotech Inc. has received confirmation from The Nasdaq Stock Market that it complies with all requirements for continued listing on the Nasdaq Capital Market as of June 24, 2025.
Business Overview and Risks: Portage Biotech is focused on developing novel biologics for cancer treatment; however, it acknowledges potential risks and uncertainties related to its business operations and future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
